Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol

The USFDA did not identify any Chemistry, Manufacturing and Controls (CMC) issues in this CRL.

39
USFDA
Picture: Pixabay

Last Updated on June 17, 2021 by The Health Master

Avenue Therapeutics, focused on the development of intravenous (IV) tramadol for the US market, announced that it has received a second Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol.

The CRL stated that the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain, and there is insufficient information to support that IV tramadol in combination with other analgesics is safe and effective for the intended patient population.

The USFDA did not identify any Chemistry, Manufacturing and Controls (CMC) issues in this CRL. A company statement said, “Avenue disagrees with the FDA’s interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol.”

Avenue Therapeutics is Cipla’s step-down associate company in the US.

Natco gets USFDA nod for Carfilzomib Injection

Lupin gets warning letter from USFDA for Somerset facility

Lupin gets USFDA nod for generic drug to treat HIV infection

Glenmark gets USFDA nod for Theophylline ER tablets

Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets

Zydus Cadila gets USFDA nod for Fluphenazine HCL Tablets

Schedules: All types of Drugs

Schedules: All types of Cosmetics

Self-use Rapid Antigen test kits: Coming soon at Pharmacies

Black fungus can be prevented with Ayush medicines: Experts

Zydus Cadila gets tentative USFDA nod for Epilepsy drug

Govt Job for Medical Officers (576 posts) under Public service Commission

Subscribe for daily free updates

Telegram
WhatsApp
Facebook
LinkedIn

Enter your email address:

Delivered by FeedBurner